MIRM · Healthcare
MIRUM PHARMACEUTICALS INC
Smart-money confidence
· 1 of 3 sources firing
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in MIRUM PHARMACEUTICALS INC? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$7.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About MIRUM PHARMACEUTICALS INC
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult…
Who's behind the signal
Every informed buyer we can see on MIRM, across all three feeds.
Hedge funds · 6
D.E. Shaw & Co
Increased +3%
AQR Capital Management
Increased +4%
Citadel Advisors
Decreased −19%
Point72 (Steve Cohen)
Decreased −76%
Millennium Management (Englander)
Decreased −21%
Tudor Investment (Paul Tudor Jones)
Decreased −81%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
MIRUM PHARMACEUTICALS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
2
Increasing
4
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+3%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+4%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−19%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−76%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−21%
0.0% of Millennium Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
−81%
0.0% of Tudor Investment's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to MIRUM PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MIRUM PHARMACEUTICALS INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime